Modulation of GLUT4 expression by oral administration of Mg2+ to control sugar levels in STZ-induced diabetic rats

2014 ◽  
Vol 92 (6) ◽  
pp. 438-444 ◽  
Author(s):  
Haniah Solaimani ◽  
Nepton Soltani ◽  
Kianoosh MaleKzadeh ◽  
Shahla Sohrabipour ◽  
Nina Zhang ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Magnesium Sulfate ◽  
Mrna Expression ◽  
Insulin Level ◽  
Diabetic Rats ◽  
In Vivo Studies ◽  
Glucose Levels ◽  
Blood Glucose Levels

It has been previously shown that oral magnesium administration decreases the levels of glucose in the plasma. However, the mechanisms are not fully understood. The aim of this study was to determine the potential role of GLUT4 on plasma glucose levels by orally administering magnesium sulfate to diabetic rats. Animals were distributed among 4 groups (n = 10 rats per group): one group served as the non-diabetic control, while the other groups had diabetes induced by streptozotocin (intraperitoneal (i.p.) injection). The diabetic rats were either given insulin by i.p. injection (2.5 U·(kg body mass)–1·day–1), or magnesium sulfate in their drinking water (10 g·L–1). After 8 weeks of treatment, we conducted an i.p. glucose tolerance test (IPGTT), measured blood glucose and plasma magnesium levels, and performed in-vitro and in-vivo insulin level measurements by radioimmunoassay. Gastrocnemius (leg) muscles were isolated for the measurement of GLU4 mRNA expression using real-time PCR. Administration of magnesium sulfate improved IPGTT and lowered blood glucose levels almost to the normal range. However, the insulin levels were not changed in either of the in-vitro or in-vivo studies. The expression of GLU4 mRNA increased 23% and 10% in diabetic magnesium-treated and insulin-treated groups, respectively. Our findings suggest that magnesium lowers blood glucose levels via increased GLU4 mRNA expression, independent to insulin secretion.

scholarly journals Oral DhHP-6 for the Treatment of Type 2 Diabetes Mellitus

2019 ◽  
Vol 20 (6) ◽  
pp. 1517 ◽  
Author(s):  
Kai Wang ◽  
Yu Su ◽  
Yuting Liang ◽  
Yanhui Song ◽  
Liping Wang
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Enzymatic Activity ◽  
Glucose Levels ◽  
Blood Glucose Levels

Type 2 diabetes mellitus (T2DM) is associated with pancreatic β-cell dysfunction which can be induced by oxidative stress. Deuterohemin-βAla-His-Thr-Val-Glu-Lys (DhHP-6) is a microperoxidase mimetic that can scavenge reactive oxygen species (ROS) in vivo. In our previous studies, we demonstrated an increased stability of linear peptides upon their covalent attachment to porphyrins. In this study, we assessed the utility of DhHP-6 as an oral anti-diabetic drug in vitro and in vivo. DhHP-6 showed high resistance to proteolytic degradation in vitro and in vivo. The degraded DhHP-6 product in gastrointestinal (GI) fluid retained the enzymatic activity of DhHP-6, but displayed a higher permeability coefficient. DhHP-6 protected against the cell damage induced by H2O2 and promoted insulin secretion in INS-1 cells. In the T2DM model, DhHP-6 reduced blood glucose levels and facilitated the recovery of blood lipid disorders. DhHP-6 also mitigated both insulin resistance and glucose tolerance. Most importantly, DhHP-6 promoted the recovery of damaged pancreas islets. These findings suggest that DhHP-6 in physiological environments has high stability against enzymatic degradation and maintains enzymatic activity. As DhHP-6 lowered the fasting blood glucose levels of T2DM mice, it thus represents a promising candidate for oral administration and clinical therapy.

scholarly journals Glycemic Variability in Diabetes Increases the Severity of Influenza

mBio ◽  
2020 ◽  
Vol 11 (2) ◽  
Author(s):  
Rebecca J. Marshall ◽  
Pornthida Armart ◽  
Katina D. Hulme ◽  
Keng Yih Chew ◽  
Alexandra C. Brown ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glycemic Variability ◽  
Endothelial Barrier ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Severe Influenza ◽  
Increased Risk ◽  
History Of

ABSTRACT People with diabetes are two times more likely to die from influenza than people with no underlying medical condition. The mechanisms underlying this susceptibility are poorly understood. In healthy individuals, small and short-lived postprandial peaks in blood glucose levels occur. In diabetes mellitus, these fluctuations become greater and more frequent. This glycemic variability is associated with oxidative stress and hyperinflammation. However, the contribution of glycemic variability to the pathogenesis of influenza A virus (IAV) has not been explored. Here, we used an in vitro model of the pulmonary epithelial-endothelial barrier and novel murine models to investigate the role of glycemic variability in influenza severity. In vitro, a history of glycemic variability significantly increased influenza-driven cell death and destruction of the epithelial-endothelial barrier. In vivo, influenza virus-infected mice with a history of glycemic variability lost significantly more body weight than mice with constant blood glucose levels. This increased disease severity was associated with markers of oxidative stress and hyperinflammation both in vitro and in vivo. Together, these results provide the first indication that glycemic variability may help drive the increased risk of severe influenza in people with diabetes mellitus. IMPORTANCE Every winter, people with diabetes are at increased risk of severe influenza. At present, the mechanisms that cause this increased susceptibility are unclear. Here, we show that the fluctuations in blood glucose levels common in people with diabetes are associated with severe influenza. These data suggest that glycemic stability could become a greater clinical priority for patients with diabetes during outbreaks of influenza.

In vitro and in vivo anti-diabetic activity of Citrullus colocynthis pulpy flesh with seeds hydro-ethanolic extract

2020 ◽  
Vol 17 (2) ◽  
Author(s):  
Aymen Owais Ghauri ◽  
Saeed Ahmad ◽  
Tayyeba Rehman
Keyword(s):  
Blood Glucose ◽  
Normal Control ◽  
Ethanolic Extract ◽  
Negative Control ◽  
Antioxidant Potential ◽  
Blood Glucose Monitoring ◽  
Glucose Levels ◽  
Blood Glucose Levels

AbstractBackgroundDiabetes is the one of the leading cause of morbidity and mortality. Traditionally phytotherapy is widely being used for diabetes treatment and highly valued. Citrus colocynthis has known anti-diabetic potential. However, anti-diabetic potential of hydro-ethanolic extract of C. colocynthis pulpy flesh with seeds is not reported yet.MethodsThe extract of C. colocynthis pulpy flesh with seeds was done by maceration method using 70% ethanol. To evaluate anti-diabetic and antioxidant potential of the seeded fruit in vitro, α-glucosidase and DPPH inhibition assays was done, respectively. In vivo study used streptozotocin (STZ) induced diabetes model of rats. Rats were randomized in five groups i. e. normal control, negative control, standard control, C. colocynthis 150 and 300 mg/kg. STZ was administered to all groups except normal control. After wards, plant extract and glibenclamide is continued for 14 days. Blood samples were collected from rat tail vein daily and from Cardiac puncture at the end of study. The blood glucose levels were monitored daily by using one-touch blood glucose monitoring system. The blood glucose level was monitored on 0, 1st, 5th, 8th, 11th, and 14th day of induction.ResultsHydro-ethanolic extract of C. colocynthis pulpy flesh with seeds was able to decolorize DPPH and therefore possess antioxidant potential, continuous administration for 14 days showed a marked decrease in serum glucose levels (p 0.01) it is found to be somewhat less effective as glibenclamide (standard control) (p 0.001). A time-dependent decrease in blood glucose levels was observed (351.3 ± 4 to 258 m/kg).ConclusionHydro-ethanolic extract of C. colocynthis pulpy flesh with seeds lowered the serum triglyceride and cholesterol levels in diabetic rats significantly as compared to negative control. The hypoglycemic effect of hydro-ethanolic extract of C. colocynthis pulpy flesh with seeds is may be due to α-glucosidase inhibition potential.

Dioscorea dumetorum-Fed Rats Exhibited Decreased Body Weight, Blood Glucose, and Insulin in STZ-induced Diabetes

2014 ◽  
Vol 4 (2) ◽  
pp. 87 ◽  
Author(s):  
Henrietta Aritetsoma Ogbunugafor ◽  
Emmanuel Emeka Ilodigwe ◽  
Daniel Lotanna Ajaghaku ◽  
Chinwe Nonyelum Ezekwesili ◽  
Chike Samuel Okafor ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Feed Intake ◽  
Weight Reduction ◽  
Blood Glucose Concentration ◽  
Insulin Level ◽  
Diabetic Control ◽  
Diabetic Rats ◽  
Male Rats ◽  
Glucose Levels ◽  
Blood Glucose Levels

Background: Preventive measures that could slow down the rising incidences of diabetes mellitus are essential. The use of neglected local foods, which have effects on this chronic disease beyond basic nutrition as dietary controls, is desirable.Objective: The effect of Dioscorea dumetorum (Kunth) Pax (Dioscoreaceae) feed on satiety, weight, blood glucose, and insulin levels were investigated in streptozotocin-induced diabetic rats.Methods: Twenty adult male rats in four groups of five were used for the experiment. Three groups – D. dumetorum, glibenclamide, and standard pellet-fed rats were induced with diabetes by i.p. administration of 50mg kg-1 streptozotocin, while the fouth group (?) served as a non-diabetic control. D. dumetorum was fed at 15g daily for ten days before induction, and after induction, feeding continued. Glibenclamide was orally administered 5mg kg-1 daily. Both the untreated and non-diabetic rats were kept on standard rat pellets. Feed intake, weight, and blood glucose concentration were monitored daily, while insulin level was measured on day two and day six after inductions. Results: Average feed intake for non-diabetic rats was 15g for D. dumetorum per day, which dropped to 10.3g after induction of diabetes. Weight of normal non-diabetic rats consistently increased (142.61 ± 4.37g – 169.43 ± 8.61g) for the duration (17 days) of the experiment. The D. dumetorum-fed rats showed weight reduction of 5.4%, glibenclamide 4.0%, and untreated diabetic 6.15%. Non-diabetic rats blood glucose levels ranged between 70 to 100mg dL-1. Streptozotocin (STZ) (i.p.) administration increased blood glucose levels from 370% to 626% in the rats. D. dumetorum-fed rats showed reduced (p<0.05) blood glucose levels of 22.6%. Glibenclamide had 5.5% reduction (p<0.05). Insulin was absent in D. dumetorum-fed rats, whereas 0.95ng ml-1 of insulin was detected in glibenclamide-administered rats. These quantities were lower (p<0.001) than 1.40ng ml-1 in the non-diabetic rats. Conclusion: This study revealed that D. dumetorum tuber caused decreased hunger, weight reduction, and displayed hypoglycemic property in diabetic rats, even after heat treatment. Its probable mechanism of anti-hyperglycemic activity might not be through increased insulin secretion.Key words: D. dumetorum, streptozotocin-induced diabetes, weight, blood glucose, insulin.

Determination the limit of postprandial blood glucose increase and the metabolism of acetylated wheat starch on healthy mice

2019 ◽  
pp. 15-22
Author(s):  
Khoa Bao Chau Thai ◽  
Huu Tien Nguyen ◽  
Huu Dung Tran
Keyword(s):  
Blood Glucose ◽  
Wheat Starch ◽  
Postprandial Blood Glucose ◽  
Control Group ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Treatment Of Diabetes ◽  
Resistant Starches

Introduction: Nowadays, resistant starches are interested as a supplement food by effecting on the limit of postprandial blood glucose increase and supporting for the diabetes treatment. Recently, we have semisynthesized the acetylated wheat starch (AWS) oriented for supporting the treatment of diabetes mellitus, which is the RS4 formed by chemical structure modification. AWS has been proved itself to show strong resistance to amylase activity in-vitro as well as to be safety in-vivo. Materials and Methods: In this study, we continued to evaluate AWS’s ability to limit postprandial blood glucose increase and determined shortchain fatty acids (SCFAs) metabolized from AWS in the gastrointestinal tract of healthy mice by HPLC. Results: the mice fed AWS exhibited a very limited increase in blood glucose levels and remained stable for 2 hours after meals comparing with the control group (mice fed natural wheat starch) (NWS). Simultaneously, the content of SCFAs produced in the caecum of the mice fed AWS was significantly higher than mice fed NWS, especially with acetic and propionic acids by 28% and 26%, respectively. Conclusion: AWS has been shown to limit postprandial hyperglycemia in mice effectively through the resistance to amylase hydrolysis in the small intestine. When going into the caecum, it is fermented to form SCFAs that provide a part of the energy for the body’s activities and to avoid rotten fermentation causing digestive disorders, which are inherent restrictions of normal high cellulose and fiber food. Key words: acetylated wheat starch, natural wheat starch, SCFA, blood glucose

Comparative effects of phlorizin and phloretin on glucose transport in the cat kidney

1962 ◽  
Vol 203 (6) ◽  
pp. 975-979 ◽  
Author(s):  
Stephen S. Chan ◽  
William D. Lotspeich
Keyword(s):  
Blood Glucose ◽  
Glucose Transport ◽  
Renal Tubule ◽  
Tubular Reabsorption ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Dog Kidney ◽  
Glucose Carrier

The net tubular reabsorption of glucose (TG) was measured simultaneously in both kidneys of the cat before, during, and after the infusion of small amounts of phlorizin and phloretin at constant rates into one renal artery. Experiments were performed at endogenous and elevated blood glucose levels. The results show that phlorizin blocks glucose transport across the renal tubule at concentrations in renal blood and tissue in the range of 10–5 to 10–7 m. These estimates agree with those for dog kidney in vivo and hamster small intestine in vitro. In addition to this high affinity of phlorizin for the tubular glucose carrier, the experiments also reveal the easily dissociable nature of the phlorizin carrier complex. When blood glucose is elevated the TG is even more sensitive to small concentrations of phlorizin. At all blood glucose levels the aglucone, phloretin, is at least ten times less effective in inhibiting TG than phlorizin itself. These findings are discussed in relation to critical groupings in the phlorizin molecule.

Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system

1998 ◽  
Vol 274 (6) ◽  
pp. G1087-G1093 ◽  
Author(s):  
Andreas W. Herling ◽  
Hans-Joerg Burger ◽  
Dietmar Schwab ◽  
Horst Hemmerle ◽  
Peter Below ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Intravenous Infusion ◽  
In Vivo Studies ◽  
Isolated Perfused Rat Liver ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Pharmacodynamic Profile ◽  
Hepatic Glucose ◽  
Glucose Output

The glucose-6-phosphatase (G-6- Pase) system catalyzes the terminal enzymatic step of gluconeogenesis and glycogenolysis. Inhibition of the G-6- Pase system in the liver is expected to result in a reduction of hepatic glucose production irrespective of the relative contribution of gluconeogenesis or glycogenolysis to hepatic glucose output. In isolated perfused rat liver, S-3483, a derivative of chlorogenic acid, produced concentration-dependent inhibition of gluconeogenesis and glycogenolysis in a similar concentration range. In fed rats, glucagon-induced glycogenolysis resulted in hyperglycemia for nearly 2 h. Intravenous infusion of 50 mg ⋅ kg−1 ⋅ h−1S-3483 prevented the hyperglycemic peak and subsequently caused a further lowering of blood glucose. In 24-h starved rats, in which normoglycemia is maintained predominantly by gluconeogenesis, intravenous infusion of S-3483 resulted in a constant reduction of blood glucose levels. Intrahepatic concentrations of glucose-6-phosphate (G-6- P) and glycogen were significantly increased at the end of both in vivo studies. In contrast, lowering of blood glucose in starved rats by 3-mercaptopicolinic acid was accompanied by a reduction of G-6- P and glycogen. Our results demonstrate for the first time in vivo a pharmacologically induced suppression of hepatic G-6- P activity with subsequent changes in blood glucose levels.

scholarly journals Evaluation ofMallotus oppositifoliusMethanol Leaf Extract on the Glycaemia and Lipid Peroxidation in Alloxan-Induced Diabetic Rats: A Preliminary Study

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
C. O. Nwaehujor ◽  
I. I. Ezeigbo ◽  
F. C. Nwinyi
Keyword(s):  
Lipid Peroxidation ◽  
Antioxidant Activity ◽  
Blood Glucose ◽  
Oral Treatment ◽  
Fasting Blood Glucose ◽  
Diabetic Rats ◽  
Albino Rats ◽  
Glucose Levels ◽  
Blood Glucose Levels

Objective. Mallotus oppositifolius(Geiseler) Müll. Arg. (Euphorbiaceae) is folklorically used to “treat” diabetic conditions in some parts of Nigeria therefore the study, to investigate the extract of the leaves for activities on hyperglycaemia, lipid peroxidation, and increased cholesterol levelsin vivoin alloxan diabetic rats as well as its potential antioxidant activityin vitro.Methods. Albino rats (240–280 g) were given an injection of 120 mg/kg body weight, i.p. of alloxan monohydrate. After 8 days, diabetic animals with elevated fasting blood glucose levels (>9 mmol/L) were considered and selected for the study.Results. Oral treatment with the extract administered every 12 h by gavage at doses of 100, 200, and 400 mg/kg of the extract to the test rats, for 14 days, resulted in a significant dose-dependent decrease in blood glucose levels from 12.82 ± 1.02 mmol/dL to 4.92 ± 2.01 mmol/dL at the highest dose of 400 mg/kg compared to the control drug and glibenclamide as well as attendant significant decline in diabetic rats employed in the study.Conclusion. The extract also showedin vitroconcentration-dependent antioxidant activity following the 1,1-diphenyl-2-picryl-hydrazyl (DPPH) and ferric reducing assays. Findings further suggest the presence of active antidiabetic and antioxidant principles inM. oppositifoliusleaves.

scholarly journals Eurotium Cristatum Fermented Okara as a Potential Food Ingredient to Combat Diabetes

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Li Yan Chan ◽  
Masaki Takahashi ◽  
Pei Jean Lim ◽  
Shinya Aoyama ◽  
Saneyuki Makino ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Food Ingredient ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Reduce Blood Glucose ◽  
Good Nutrition ◽  
Physical Attributes

AbstractType 2 diabetes mellitus (T2DM) is a chronic disease, and dietary modification is a crucial part of disease management. Okara is a sustainable source of fibre-rich food. Most of the valorization research on okara focused more on the physical attributes instead of the possible health attributes. The fermentation of okara using microbes originated from food source, such as tea, sake, sufu and yoghurt, were explored here. The aim of this study is to investigate fermented okara as a functional food ingredient to reduce blood glucose levels. Fermented and non-fermented okara extracts were analyzed using the metabolomic approach with UHPLC-QTof-MSE. Statistical analysis demonstrated that the anthraquinones, emodin and physcion, served as potential markers and differentiated Eurotium cristatum fermented okara (ECO) over other choices of microbes. The in-vitro α-glucosidase activity assays and in-vivo mice studies showed that ECO can reduce postprandial blood glucose levels. A 20% ECO loading crispy snack prototype revealed a good nutrition composition and could serve as a fundamental formulation for future antidiabetes recipe development, strengthening the hypothesis that ECO can be used as a novel food ingredient for diabetic management.

Sign in / Sign up

Export Citation Format

Share Document